Myriad Genetics Expands Minimal Residual Disease Testing for Three Cancer Types
The whole-genome sequencing assay is now available for breast, colorectal, and renal cancers following new clinical study results.
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
New PATHOMIQ AI integration helps clinicians tailor active surveillance with greater confidence
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the U.S.
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
Analytical validation of FirstGene Multiple Prenatal Screen published in Clinical Chemistry
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test.
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
Podium presentation showcases the clinical application of Precise™ MRD
